ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma"

  • Abstract Number: 1190 • ACR Convergence 2022

    Multimorbidity in Systemic Sclerosis: Burden and Trends in Prevalence from an Incident Population-based Cohort (1980-2018)

    Ashima Makol1, Sara Achenbach1, Alicia Hinze2, Tina Gunderson3 and Cynthia Crowson4, 1Mayo Clinic, Rochester, MN, Rochester, MN, 2Mayo Clinic - Rochester, MN, Rochester, MN, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic, Eyota, MN

    Background/Purpose: To estimate the prevalence and trends of multimorbidity (MM; the presence of ≥2 morbidities) in a population-based cohort of patients with Systemic sclerosis (SSc)…
  • Abstract Number: 1662 • ACR Convergence 2022

    Nationwide Distribution of Other Connective Tissue Disease (OCTD) and Systemic Sclerosis (SSc) in Areas of Environmental Concern

    Noelle Kosarek1, Megan Romano2, Robert Simms3, Angeline Andrew4, Erika Moen4, Patricia pioli4 and Michael Whitfield5, 1Dartmouth Geisel School of Medicine, Lebanon, NH, 2Dartmouth College, Lebanon, NH, 3Dartmouth Hitchcock Medical Center, Lebanon, NH, 4Geisel School of Medicine at Dartmouth, Lebanon, NH, 5Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH

    Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs, vascular abnormalities, and autoantibody formation. The etiology…
  • Abstract Number: 2190 • ACR Convergence 2022

    Characterizing Compensatory Cognitive Strategy Use in People with Systemic Sclerosis

    Yen Chen1, Alain Lescoat2, Dinesh Khanna3 and Susan Murphy4, 1University of Michigan, Ann Arbor, MI, 2CHU Rennes - University Rennes 1, Rennes, France, 3Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 4University of Michigan, Grosse Ile, MI

    Background/Purpose: Individuals with systemic sclerosis (SSc) report cognitive problems that worsen symptoms and daily activity performance. Compensatory cognitive strategies (CCS) are commonly taught to help…
  • Abstract Number: 1090 • ACR Convergence 2021

    Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center

    Diana Prieto-Peña1, Belén Atienza-Mateo2, Miguel Ángel gonzalez-Gay3, Ricardo Blanco4 and Marcos Lopez-Hoyos5, 1Hospital Universitario Marqués de Valdecilla, santander, Spain, 2Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 5Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain

    Background/Purpose: Immunoblot assays are increasingly used in clinical practice as part of the diagnostic armamentarium of systemic autoimmune rheumatic diseases (SARDs). Our aim was to…
  • Abstract Number: 1852 • ACR Convergence 2021

    Healthcare Utilization and Economic Burden in Systemic Sclerosis

    Leonardo Martin Calderon1, Mitali Chaudhary1 and Janet Pope2, 1Western University, London, ON, Canada, 2University of Western Ontario, London, ON, Canada

    Background/Purpose: Systemic Sclerosis (SSc) is a multi-system autoimmune disease, characterized by vasculopathy, fibrosis of the skin and internal organs, and autoimmunity with distinct antibodies. SSc…
  • Abstract Number: 1367 • ACR Convergence 2021

    Associations of Esophageal Dysmotility Patterns with Extra-intestinal Features in Patients with Systemic Sclerosis

    Ana Tucker1, Jamie Perin2, Elizabeth Volkmann3, Ami Shah4, John Pandolfino5 and Zsuzsanna McMahan4, 1Medical University of South Carolina, Charleston, SC, 2Johns Hopkins University, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, 4Johns Hopkins Rheumatology, Baltimore, MD, 5Northwestern University, Chicago, IL

    Background/Purpose: The gastrointestinal (GI) tract is the most commonly affected internal organ in systemic sclerosis (SSc). SSc GI disease is heterogeneous, with some patients experiencing…
  • Abstract Number: 1854 • ACR Convergence 2021

    Disease Characteristics and Social Determinants in African Americans with Systemic Sclerosis: A Single Center Experience

    Sarah Compton, DeAnna Baker Frost, Richard Silver and Diane Kamen, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease categorized on the basis of skin involvement as either limited or diffuse cutaneous SSc, the latter…
  • Abstract Number: 1370 • ACR Convergence 2021

    Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)

    Roberta G Marangoni1, Changyong Feng1, Ashley Frazer-Abel2, Stephen Tomlinson3, Amy Wielgosz1, Katie Lutz4, Michael Pauciulo4, William Nichols4, V. Michael Holers5, Christopher Ritchlin6, R James White III1 and Benjamin Korman1, 1University of Rochester, Rochester, NY, 2University of Colorado Denver, Colorado, CO, 3Medical University of South Carolina, Charleston, SC, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5University of Colorado, Denver, CO, 6Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe vascular complication of systemic sclerosis (SSc) and a major cause of mortality. Despite significant advances in the…
  • Abstract Number: 1856 • ACR Convergence 2021

    Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc

    Ranjitha Karanth1, Giuseppina Abignano2, Vishal Kakkar2, Rebecca Ross2, Christopher Denton3 and Francesco Del Galdo2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, LTHT, Leeds, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) carries a highly variable prognosis and to date there are no stratification tools to predict clinical outcomes. Evidence suggests…
  • Abstract Number: 1371 • ACR Convergence 2021

    Symptom Management in Systemic Sclerosis: A Pilot Study of a Web-based Intervention Using Peer-Health Coaches

    Susan Murphy1, Yen Chen2, Mary Alore2, Sheri Hicks2 and Dinesh Khanna2, 1University of Michigan, Grosse Ile, MI, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: People with systemic sclerosis (SSc) have a high burden of chronic symptoms that have dramatic effects on function and quality of life. Fatigue, along…
  • Abstract Number: 0142 • ACR Convergence 2021

    Description of a Scleroderma Cohort and Management of Lung Disease Risk at a Rural Academic Medical Center

    Jenna Marinock1, P. Daniel Nicholas2, Kirsten Koons3, Rakesh Kriplani4, Andrea Berger4 and David Bulbin5, 1Geisinger Commonwealth School of Medicine, Philadelphia, PA, 2Geisinger Medical Center, Danville, PA, 3Geisinger Medical Center, Lewisburg, PA, 4Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, 5Geisinger Health System, Danville, PA

    Background/Purpose: Systemic sclerosis interstitial lung disease (SSc-ILD) and pulmonary hypertension (SSc-PH) are leading causes of morbidity and mortality in patients with SSc. Few screening guidelines…
  • Abstract Number: 1372 • ACR Convergence 2021

    Outcomes and Risk Factors for Respiratory Failure in Patients with Scleroderma Associated with ILD

    Soumyasri Kambhatla1, Augustine Manadan2 and Amy Trang2, 1Rush University, Chicago, IL, 2Rush University Medical Center, Chicago, IL

    Background/Purpose: Scleroderma is associated with underlying ILD. About 48% those with diffuse cutaneous SSc and 26% of those with limited cutaneous SSc were found to…
  • Abstract Number: 0391 • ACR Convergence 2021

    High Frequency Ultrasound Imaging of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis: An Objective Outcome Measure to Track Change over Time

    Elizabeth Marjanovic1, Calvin Heal1, Tonia Moore1, Joanne Manning2, Sarah Wilkinson1, Graham Dinsdale2, Mark Dickinson1, Jack Wilkinson1, Ariane Herrick3 and Andrea Murray1, 1University of Manchester, Manchester, United Kingdom, 2Salford Royal NHS Foundation Trust, Manchester, United Kingdom, 3University of Manchester, Salford, United Kingdom

    Background/Purpose: There are currently no validated objective measures of systemic sclerosis (SSc)-related skin thickening and this hampers clinical trials of potential new treatments. The modified…
  • Abstract Number: 1377 • ACR Convergence 2021

    Assessment of Autoantibodies and Clinical Associations in SSc Patients with ANA Positivity & Negative for Prototypic Autoantibodies

    Karen Kruzer1, Roberta G Marangoni1, Ilana Heckler2, Aya Elhage2, Varga John3, Monique Hinchcliff4, Mary Carns5, Kathleen Aren5, Amy Wielgosz1, Marc Nuzzo6, Iswariya Venkataraman2 and Benjamin Korman1, 1University of Rochester, Rochester, NY, 2EUROIMMUN US, Mountain Lakes, NJ, 3University of Michigan, Ann Arbor, MI, 4Yale School of Medicine, Westport, CT, 5Northwestern University Division of Rheumatology, Chicago, IL, 6Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Systemic sclerosis (SSc) is a clinically heterogenous disease typically characterized by a positive ANA (ANA+), and prototypical antibodies including anti-centromere, anti-topoisomerase, and anti-RNA polymerase…
  • Abstract Number: 0392 • ACR Convergence 2021

    Faecal Incontinence in Scleroderma: Prevalence, Impact and Response to Sacral Neuromodulation in an Single Centre Observational Cohort

    Nikhil Suresh1, Ranjitha Karanth1, David Jayne2, Giuseppina Abignano3 and Francesco Del Galdo3, 1LIRMM, Leeds, United Kingdom, 2Colorectal Surgery / St James University Hospital, Leeds, United Kingdom, 3University of Leeds, Leeds, United Kingdom

    Background/Purpose: Scleroderma (SSc) is a chronic autoimmune disorder involving multiple organs, the gastrointestinal system (GI) commonly involved in up to 90% of the sufferers. Faecal…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology